Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:49 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients
NCT02085265 · Sunnybrook Health Sciences Centre · PHASE2 · terminated · last registry update 2025-05-06 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of recruitment.” | – | Registry record, Sunnybrook Health Sciences Centre |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ACE within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-10-30Phase 3 first posted: Women and Infants Hospital of Rhode Island, Enalapril (NCT07222852)
- 2025-07-22Results posted on the registry: University of Alabama at Birmingham, Perindopril + Losartan (NCT03295734)
- 2025-02-17Also stopped (withdrawn): Nova Scotia Health Authority, Intralesional enalaprilat injection (NCT05259137)
- 2024-11-06Also stopped (terminated): University of Alberta, labetalol/hydralazine/enalapril (NCT02281838)
- 2024-07-16Results posted on the registry: University of Wisconsin, Madison, Anti-Hypertensive (NCT05479097)
- 2024-07-16Results posted on the registry: University of Maryland, Baltimore, pravastatin and chenodeoxycholic acid, after metformin and placebo + valacyclovir, chenodeoxycholic acid, and enalaprilat, after polysorbate 80 and placebo (NCT04640571)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision